<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>49</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>59(12)</volume><submitter>Peter A</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Recent data suggested that sex hormone-binding globulin (SHBG) levels decrease when fat accumulates in the liver and that circulating SHBG may be causally involved in the pathogenesis of type 2 diabetes in humans. In the present study, we investigated mechanisms by which high SHBG may prevent development to diabetes.&lt;h4>Research design and methods&lt;/h4>Before and during a 9-month lifestyle intervention, total body and visceral fat were precisely measured by magnetic resonance (MR) tomography and liver fat was measured by (1)H-MR spectroscopy in 225 subjects. Insulin sensitivity was estimated from a 75-g oral glucose tolerance test (IS(OGTT)) and measured by a euglycemic hyperinsulinemic clamp (IS(clamp), n = 172). Insulin secretion was measured during the OGTT and an ivGTT (n = 172).&lt;h4>Results&lt;/h4>SHBG levels correlated positively with insulin sensitivity (IS(OGTT), P = 0.037; IS(clamp), P = 0.057), independently of age, sex, and total body fat. In a multivariate model, these relationships were also significant after additional adjustment for levels of the adipokine adiponectin and the hepatokine fetuin-A (IS(OGTT), P = 0.0096; IS(clamp), P = 0.029). Adjustment of circulating SHBG for liver fat abolished the relationships of SHBG with insulin sensitivity. In contrast, circulating SHBG correlated negatively with fasting glycemia, before (r = -0.17, P = 0.009) and after (r = -0.14, P = 0.04) adjustment for liver fat. No correlation of circulating SHBG with adjusted insulin secretion was observed (OGTT, P = 0.16; ivGTT, P = 0.35). The SNP rs1799941 in SHBG was associated with circulating SHBG (P ≤ 0.025) but not with metabolic characteristics (all P > 0.18).&lt;h4>Conclusions&lt;/h4>Possible mechanisms by which high circulating SHBG prevents the development of type 2 diabetes involve regulation of fasting glycemia but not alteration of insulin secretory function.</pubmed_abstract><journal>Diabetes</journal><pagination>3167-73</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2992779</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.</pubmed_title><pmcid>PMC2992779</pmcid><pubmed_authors>Machann J</pubmed_authors><pubmed_authors>Peter A</pubmed_authors><pubmed_authors>Schleicher E</pubmed_authors><pubmed_authors>Haring HU</pubmed_authors><pubmed_authors>Stefan N</pubmed_authors><pubmed_authors>Schick F</pubmed_authors><pubmed_authors>Machicao F</pubmed_authors><pubmed_authors>Fritsche A</pubmed_authors><pubmed_authors>Kantartzis K</pubmed_authors><pubmed_authors>Staiger H</pubmed_authors><view_count>49</view_count></additional><is_claimable>false</is_claimable><name>Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.</name><description>&lt;h4>Objective&lt;/h4>Recent data suggested that sex hormone-binding globulin (SHBG) levels decrease when fat accumulates in the liver and that circulating SHBG may be causally involved in the pathogenesis of type 2 diabetes in humans. In the present study, we investigated mechanisms by which high SHBG may prevent development to diabetes.&lt;h4>Research design and methods&lt;/h4>Before and during a 9-month lifestyle intervention, total body and visceral fat were precisely measured by magnetic resonance (MR) tomography and liver fat was measured by (1)H-MR spectroscopy in 225 subjects. Insulin sensitivity was estimated from a 75-g oral glucose tolerance test (IS(OGTT)) and measured by a euglycemic hyperinsulinemic clamp (IS(clamp), n = 172). Insulin secretion was measured during the OGTT and an ivGTT (n = 172).&lt;h4>Results&lt;/h4>SHBG levels correlated positively with insulin sensitivity (IS(OGTT), P = 0.037; IS(clamp), P = 0.057), independently of age, sex, and total body fat. In a multivariate model, these relationships were also significant after additional adjustment for levels of the adipokine adiponectin and the hepatokine fetuin-A (IS(OGTT), P = 0.0096; IS(clamp), P = 0.029). Adjustment of circulating SHBG for liver fat abolished the relationships of SHBG with insulin sensitivity. In contrast, circulating SHBG correlated negatively with fasting glycemia, before (r = -0.17, P = 0.009) and after (r = -0.14, P = 0.04) adjustment for liver fat. No correlation of circulating SHBG with adjusted insulin secretion was observed (OGTT, P = 0.16; ivGTT, P = 0.35). The SNP rs1799941 in SHBG was associated with circulating SHBG (P ≤ 0.025) but not with metabolic characteristics (all P > 0.18).&lt;h4>Conclusions&lt;/h4>Possible mechanisms by which high circulating SHBG prevents the development of type 2 diabetes involve regulation of fasting glycemia but not alteration of insulin secretory function.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Dec</publication><modification>2024-11-20T15:38:39.988Z</modification><creation>2019-03-27T00:36:56Z</creation></dates><accession>S-EPMC2992779</accession><cross_references><pubmed>20841609</pubmed><doi>10.2337/db10-0179</doi></cross_references></HashMap>